The Evaluation of the Efficacy and Tolerability of FASLODEX (fulvestrant) and AROMASIN (exemestane) in Hormone Receptor Positive Postmenopausal Women with Advanced Breast Cancer - EFECT

Exclusion Criteria

• - Previous treatment with Faslodex (fulvestrant) or Aromasin (exemestane)
• - Any hormonal therapy used to modify the course of an additional medical condition after prior treatment with a non-steroidal aromatase inhibitor
• - Treatment with an investigational or non-approved drug within one month
• - An existing serious disease, illness, or condition that will prevent participation or
• compliance with study procedures
• - A history of allergies to any active or inactive ingredients of Faslodex or Exemestane (i.e. castor oil or Mannitol)